ATE193541T1 - Insulinotropes hormon - Google Patents

Insulinotropes hormon

Info

Publication number
ATE193541T1
ATE193541T1 AT89910254T AT89910254T ATE193541T1 AT E193541 T1 ATE193541 T1 AT E193541T1 AT 89910254 T AT89910254 T AT 89910254T AT 89910254 T AT89910254 T AT 89910254T AT E193541 T1 ATE193541 T1 AT E193541T1
Authority
AT
Austria
Prior art keywords
derivatives
insulinotropic hormone
insulinotropic
hormone
glp
Prior art date
Application number
AT89910254T
Other languages
English (en)
Inventor
Joel F Habener
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE193541T1 publication Critical patent/ATE193541T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89910254T 1989-03-20 1989-03-20 Insulinotropes hormon ATE193541T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1989/001121 WO1990011296A1 (en) 1989-03-20 1989-03-20 Insulinotropic hormone
CA000594350A CA1341363C (en) 1989-03-20 1989-03-21 Insulinotropic hormone

Publications (1)

Publication Number Publication Date
ATE193541T1 true ATE193541T1 (de) 2000-06-15

Family

ID=25672535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89910254T ATE193541T1 (de) 1989-03-20 1989-03-20 Insulinotropes hormon

Country Status (6)

Country Link
EP (1) EP0464022B1 (de)
JP (1) JPH04504246A (de)
AT (1) ATE193541T1 (de)
CA (1) CA1341363C (de)
DE (1) DE68929217T2 (de)
WO (1) WO1990011296A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
USRE37302E1 (en) * 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
BR9306551A (pt) * 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
DE69327495T2 (de) * 1992-07-13 2000-06-15 Nisshin Flour Milling Co., Ltd. Arzneimittel die Glicentin als aktiven Wirkstoff enthalten
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
WO1995005848A1 (en) * 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
EP0658568A1 (de) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (de) * 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1840134B1 (de) * 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 Derivate
EP1100530B1 (de) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
ATE509028T1 (de) 1999-03-15 2011-05-15 Novo Nordisk As Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
AU2004266757A1 (en) 2003-08-21 2005-03-03 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP1694356B1 (de) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulierung der nahrungspräferenz mit glp-1-agonisten
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
MX2007014088A (es) 2005-05-10 2008-02-07 Fournier Lab Sa Uso novedoso de los agonistas del receptor x hepatico.
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
JP2010538981A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独でまたはペプチドＧｌｙ−Ａｒｇ−Ｇｌｙ−Ａｓｐ−Ａｓｎ−Ｐｒｏ−ＯＨと組み合わせて用いる、治療剤としてのペプチドＨｉｓ−Ｓｅｒ−Ｌｅｕ−Ｇｌｙ−Ｌｙｓ−Ｔｒｐ−Ｌｅｕ−Ｇｌｙ−Ｈｉｓ−Ｐｒｏ−Ａｓｐ−Ｌｙｓ−Ｐｈｅの使用
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
WO2010066734A1 (en) 2008-12-08 2010-06-17 Novo Nordisk A/S Counter current purification of polypeptides
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK283180A (da) * 1980-07-01 1982-01-02 Novo Industri As Polypeptider og derivater deraf
ATE110083T1 (de) * 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.

Also Published As

Publication number Publication date
DE68929217T2 (de) 2000-11-30
JPH04504246A (ja) 1992-07-30
DE68929217D1 (en) 2000-07-06
EP0464022B1 (de) 2000-05-31
WO1990011296A1 (en) 1990-10-04
EP0464022A1 (de) 1992-01-08
CA1341363C (en) 2002-05-28
EP0464022A4 (en) 1992-04-15

Similar Documents

Publication Publication Date Title
ATE193541T1 (de) Insulinotropes hormon
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
NO954055L (no) Glukogen-liknende insulintropiske peptidanaloger, sammensetninger og fremgangsmåter for anvendelse derav
DE69327309D1 (de) Verwendung eines peptids
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
PH23014A (en) Novel insulin derivatives,their use and pharmaceutical agents for the treatment of diabetes mellitus
NO940436L (no) Forlenget avgivelse av peptider
ATE110083T1 (de) Insulinotropes hormon.
DK358384A (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
DK160460C (da) Insulinpraeparat til nasal eller rektal administration og anvendelse af et insulinderivat til fremstilling af praeparatet
MX9303554A (es) Peptido similar al glucagon y derivados de insulinotropina.
DK0964692T3 (da) Anvendelse af GLP 1 eller analoger til behandling af myocardialt infarkt
DE69518154D1 (de) Behandlung von diabetes
DK283180A (da) Polypeptider og derivater deraf
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
NO891156L (no) Superaktive humane insulinanaloger.
ATE98990T1 (de) Menschlicher prourokinase aehnliches polypeptid.
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time